AC Immune (ACIU) Competitors

Dianthus Therapeutics (NASDAQ:DNTH) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.

Which has more risk and volatility, DNTH or ACIU?

Dianthus Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Does the media prefer DNTH or ACIU?

In the previous week, Dianthus Therapeutics had 17 more articles in the media than AC Immune. MarketBeat recorded 19 mentions for Dianthus Therapeutics and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.23 beat Dianthus Therapeutics' score of 0.39 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
AC Immune	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of DNTH or ACIU?

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 8.2% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has higher earnings & valuation, DNTH or ACIU?

Dianthus Therapeutics has higher earnings, but lower revenue than AC Immune. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$6.52M	94.20	-$43.56M	-$2.88	-6.64
AC Immune	$28.30M	6.21	-$60.41M	-$0.58	-3.02

Is DNTH or ACIU more profitable?

AC Immune has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-1,250.32%	-21.68%	-20.88%
AC Immune	N/A	-28.26%	-18.98%

Do analysts rate DNTH or ACIU?

Dianthus Therapeutics presently has a consensus target price of $53.00, indicating a potential upside of 177.34%. AC Immune has a consensus target price of $10.00, indicating a potential upside of 471.43%. Given AC Immune's higher possible upside, analysts clearly believe AC Immune is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22
AC Immune	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer DNTH or ACIU?

AC Immune received 234 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 96.55% of users gave Dianthus Therapeutics an outperform vote while only 62.68% of users gave AC Immune an outperform vote.

Company	Underperform	Outperform
Dianthus Therapeutics	Outperform Votes 28 96.55%	Underperform Votes 1 3.45%
AC Immune	Outperform Votes 262 62.68%	Underperform Votes 156 37.32%

Summary

AC Immune beats Dianthus Therapeutics on 10 of the 19 factors compared between the two stocks.